MARKET

CYAD

CYAD

Celyad
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.38
-0.02
-0.16%
Closed 16:00 02/21 EST
OPEN
10.44
PREV CLOSE
10.40
HIGH
10.46
LOW
10.34
VOLUME
16.29K
TURNOVER
--
52 WEEK HIGH
22.99
52 WEEK LOW
8.10
MARKET CAP
144.73M
P/E (TTM)
-3.1624
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CYAD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CYAD stock price target is 42.25 with a high estimate of 43.92 and a low estimate of 39.92.

EPS

CYAD News

More
  • Celyad Announces February and March 2020 Conference Schedule
  • GlobeNewswire · 5d ago
  • Celyad: Assessing This CAR-T Concern
  • Seeking Alpha - Article · 02/04 23:20
  • Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS
  • GlobeNewswire · 01/13 06:00
  • Celyad updates on NKG2D-based CAR-T therapy
  • seekingalpha · 12/10/2019 18:19

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About CYAD

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
More

Webull offers kinds of Celyad SA stock information, including NASDAQ:CYAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYAD stock news, and many more online research tools to help you make informed decisions.